TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC

Summary

This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC), while exploring potential biomarkers associated with treatment response.

Timeline

Start

2025-06

Primary completion

2027-06

Completion

2027-12

Drugs

Indications